TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07219459: Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Sponsor: CatalYm GmbH · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 104 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07219459 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07219459 Rescue Dossier →